

Maria Vittoria Dieci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4295583/publications.pdf>

Version: 2024-02-01

89
papers

3,985
citations

172386

29
h-index

138417

58
g-index

92
all docs

92
docs citations

92
times ranked

6219
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	3.2	36
2	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	2.7	47
3	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
4	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	1.0	1
5	HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	46
6	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 2146-2158.	0.6	9
7	Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 547-547.	0.8	3
8	Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. <i>Cells</i> , 2021, 10, 223.	1.8	115
9	Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies. , 2021, , .		0
10	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	3.2	9
11	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 12.	2.3	9
12	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	2.3	13
13	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 625636.	1.3	8
14	Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2021, 14, 160-164.	0.3	3
15	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , 2021, 147, 120-127.	1.3	15
16	Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?. <i>Cancers</i> , 2021, 13, 1655.	1.7	6
17	Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network during the first and second pandemic waves.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6511-6511.	0.8	1
18	Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2021-2021.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 98, 102222.	3.4	21
20	HER2: a never ending story. <i>Lancet Oncology</i> , The, 2021, 22, 1051-1052.	5.1	13
21	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2021, 7, 101.	2.3	44
22	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021, 154, 21-29.	1.3	8
23	Expert Discussion: Immunotherapy in Breast Cancer – Ready for Prime Time?. <i>Breast Care</i> , 2021, 16, 188-191.	0.8	0
24	Evolution of HER2-low expression from primary to recurrent breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 137.	2.3	94
25	Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. <i>Frontiers in Oncology</i> , 2021, 11, 705927.	1.3	10
26	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
27	Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available Evidence and Clinical Implications. <i>Cancer Treatment Reviews</i> , 2021, 102, 102323.	3.4	17
28	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
29	Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. <i>ESMO Open</i> , 2020, 5, e000843.	2.0	14
30	Should triple-positive breast cancer be recognized as a distinct subtype?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1011-1014.	1.1	15
31	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, e1355-e1362.	1.9	8
32	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	1.7	29
33	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	0.8	69
34	The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8102.	1.8	24
35	<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	3.2	17
36	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020, 88, 102064.	3.4	41

#	ARTICLE	IF	CITATIONS
37	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage III patients treated with standard therapy. <i>European Journal of Cancer</i> , 2020, 136, 7-15.	1.3	32
38	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	0.9	4
39	Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2- breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 562-562.	0.8	5
40	Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS598-TPS598.	0.8	22
41	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 717-732.	1.1	8
42	An overview of immune checkpoint inhibitors in breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	4
43	Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. <i>Journal of Women's Health</i> , 2019, 28, 544-550.	1.5	9
44	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq0 0 0 rgBT /Overlock 10 T 1137.	1.7	22
45	BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. <i>Breast</i> , 2019, 47, 77-84.	0.9	19
46	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019, 24, e1055-e1069.	1.9	36
47	Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives. <i>Cancers</i> , 2019, 11, 1401.	1.7	70
48	Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. <i>Frontiers in Oncology</i> , 2019, 9, 452.	1.3	43
49	Electrochemotherapy of superficial tumors – Current status:. <i>Seminars in Oncology</i> , 2019, 46, 173-191.	0.8	80
50	Escalation and de-escalation in HER2 positive early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 35-42.	1.1	11
51	Neoplastic Pericardial Effusion: A Monocentric Retrospective Study. <i>Journal of Palliative Medicine</i> , 2019, 22, 691-695.	0.6	9
52	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
53	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
54	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019, 17, 207.	2.3	4

#	ARTICLE	IF	CITATIONS
55	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1â€“T3, N0â€“N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019, 24, 1424-1431.	1.9	22
56	Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. <i>Journal of Neuro-Oncology</i> , 2018, 138, 369-382.	1.4	19
57	Olaparib for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 519-530.	1.1	37
58	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018, 37, 36-41.	0.9	31
59	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
60	First Prospective Multicenter Italian Study on the Impact of the 21â€“Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 297-305.	1.9	8
61	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018, 3, e000389.	2.0	4
62	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018, 23, 1289-1299.	1.9	31
63	Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018, 20, 62.	2.2	54
64	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 507-507.	0.8	6
65	Prognostic impact of proliferation for resected early stage â€“pureâ€“™ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017, 35, 21-26.	0.9	16
66	Beyond breast specificâ€“Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. <i>Journal of Neuro-Oncology</i> , 2017, 131, 369-376.	1.4	8
67	Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 3723-3728.	0.5	3
68	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002201.	3.9	300
69	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. <i>Cancer Treatment Reviews</i> , 2016, 46, 9-19.	3.4	84
70	The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 111-120.	0.6	2
71	Whole exome sequencing of rare aggressive breast cancer histologies. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 21-32.	1.1	38
72	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015, 20, 1001-1010.	1.9	85

#	ARTICLE	IF	CITATIONS
73	Preoperative Carboplatin+Paclitaxel+Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 2881-2887.	0.7	14
74	PIK3CA: a Target or a Marker in Breast Cancers. <i>Current Breast Cancer Reports</i> , 2015, 7, 161-169.	0.5	6
75	Clinical development of mTOR inhibitors in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 203.	2.2	49
76	Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities. <i>Oncologist</i> , 2014, 19, 805-813.	1.9	132
77	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1041-1050.	1.1	4
78	Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. <i>Anticancer Research</i> , 2014, 34, 3657-62.	0.5	8
79	Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies. <i>Drugs</i> , 2013, 73, 1257-1265.	4.9	40
80	The Future of Chemotherapy in the Era of Personalized Medicine. <i>Current Breast Cancer Reports</i> , 2013, 5, 57-68.	0.5	2
81	Quantification of residual risk of relapse in breast cancer patients optimally treated. <i>Breast</i> , 2013, 22, S92-S95.	0.9	16
82	Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives. <i>Cancer Discovery</i> , 2013, 3, 264-279.	7.7	339
83	Landscape and evolution of therapeutic research for breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 319-324.	1.1	3
84	Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. <i>Journal of Clinical Pathology</i> , 2012, 65, 503-506.	1.0	13
85	Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, e76-e78.	0.8	118
86	Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 395-406.	0.9	70
87	Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2150-2157.	0.7	16
88	Timing for starting second-line therapy in recurrent ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 49-55.	1.1	11
89	Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management. <i>Oncologist</i> , 2008, 13, 838-844.	1.9	133